Allogeneic adipose derived stem/stromal cells (Rigshospitalet)

N/A

Report date: 2023/01/12 15:40:48

Base Information

Drug NameAllogeneic adipose derived stem/stromal cells (Rigshospitalet)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsRejection of lung transplantationKeratoconjunctivitis SiccaXerostomia +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRigshospitalet

China Registration ClassN/A

Develop Information

Active CompaniesRigshospitalet

Inactive CompaniesN/A

Active IndicationsRejection of lung transplantationKeratoconjunctivitis SiccaXerostomia +[7]

Inactive IndicationsN/A

Other Information

ATC CodeN/A